NCT05498636尚未招募1 期
Selinexor Combined With Prednisone, Etoposide, and Lenalidomide as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for Refractory Diffuse Large B-cell Lymphoma With p53 and/or c-Myc Expression
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 67
- 试验地点
- 1
- 主要终点
- ORR
研究概览
简要总结
This study is a phase II multi-center prospective clinical trail which investigates the efficacy and safety of Selinexor combined with prednisone, etoposide and lenalidomide in the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patient with high p53 and/or c-myc expression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 80 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Any of the following as defined by the WHO, 2016 lymphoid neoplasm classifications and histologically confirmed：Diffuse large B-cell lymphoma with p53 and/ or c-Myc protein overexpression.
- •Note: a. The cutoff value for p53 protein overexpression by immunohistochemistry (IHC) is 50%; cutoff value for c-Myc protein overexpression is 30-40%; b. For patients with high expression of C-Myc, dual-color FISH probes detection method should be used to check whether there is Myc and BCL2 gene rearrangement, which is cut by 5%; c. We need 5-10 pathological white films with a thickness of 5-10 um for review.
- •Patients who cannot tolerate or are unwilling to undergo intensive salvage therapy due to age or frailty; patients who have received at most three prior lines of regimen, in which stem cell transplantation is considered first-line.
- •With a life expectancy of ≥ 3 months
- •Age ≥ 18 years
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- •At least 1 evaluable or measurable lesion that meets Lugano2014 criteria [Evaluable lesions: PET/CT examination showed increased uptake in lymph nodes or extranodal areas (higher than that in the liver), and pet/ct features were consistent with lymphoma. Measurable disease: Nodular lesions with longest diameter (LDi) greater than > 15mm or extranodal lesion with LDi >10mm. and FDG-PET positive lesions]
- •All screening laboratory tests should be performed according to the protocol and within 14 days before enrollment. Screening laboratory values must meet the following criteria： Routine blood tests (no blood transfusion, no G-CSF, no drug correction within 14 days before screening) : a. Hb≥80g/L；b.ANC≥1.0×109/L；c.PLT≥75×109/L.
- •Blood biochemistry: a.TBIL≤1.5×upper limit of normal (ULN), or TBIL≤3×ULN(if due to liver involvement); b. ALT and AST≤3×ULN, or AST and ALT≤5.0 x ULN(if due to liver involvement); c. Serum creatinine ≤1.5×ULN, or Estimated creatinine clearance ≥ 50 mL/min (calculated using the formula of Cockcroft-Gault).
- •Coagulation function (unless the subject is receiving anticoagulant treatment and the coagulation parameters (PT/INR and APTT) are within the expected range of anticoagulant treatment at the time of screening): INR≤1.5×ULN; APTT≤1.5×ULN.
- •Written informed consent of the patient
排除标准
- •Patient with hemophagocytic syndrome
- •With uncontrolled serious active infections, including active tuberculosis
- •Known to have central nervous system (CNS), testicular, breast lymphoma; Patients with massive pleural and peritoneal effusion
- •Previous treatment with Selinexor or lenalidomide in the past 6 months
- •Previous treatment with allogeneic hematopoietic stem cell transplantation or allogeneic organ transplantation.
- •Autologous hematopoietic stem cell transplantation was performed within 6 months prior to initiation of treatment.
- •Major surgery <28 days of C1D
- •Live vaccine (excluding attenuated influenza vaccine) within 28 days before study treatment.
- •Ongoing participation in another clinical study, or planned initiation of treatment in this study less than 4 weeks from the end of treatment in the previous clinical study.
- •Patients with serious medical diseases, such as organic heart disease, resulting in clinical symptoms or cardiac dysfunction (≥NYHA grade 2), a history of myocardial infarction within 6 months prior to screening, echocardiographic ejection fraction < 50%, and severe thromboembolic diseases.
- •Positive HIV serologies before inclusion.
- •Other malignant tumors in the past 5 years, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, and gastrointestinal intramucosal carcinoma after radical treatment.
- •Additional systemic antitumor therapy may be accepted during the study period.
- •Other conditions that patients considered unsuitable for inclusion by the researchers.
结局指标
主要结局
ORR
时间窗: At the end of Cycle 4 (each cycle is 28 days)
overall response rate after 4 cycles of SPEL regimen
CR rate
时间窗: At the end of Cycle 4 (each cycle is 28 days)
complete remission rate after 4 cycles of SPEL regimen
次要结局
- AE(from the first dose of SPEL regimen to 3 months after last dose of the regimen)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)Diffuse Large B Cell LymphomaNCT06517511Sun Yat-sen University42
撤回
1 期
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)Relapsed or Refractory Diffuse Large B-Cell LymphomaNCT04607772Karyopharm Therapeutics Inc350
撤回
2 期
Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplantMyeloma-Associated AmyloidosisMultiple MyelomaNCT05820763Washington University School of Medicine
已完成
1 期
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaNCT02299518Alice Mims23
暂停
2 期
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaMultiple MyelomaNCT04661137Hackensack Meridian Health96